GSK
GlaxoSmithKline PLC
50.50$
+0.3%
vs. previous close
Closing price · As of: Aug 13, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 27.9% | 30.0% | 26.8% | 26.9% | 29.9% | 31.5% | 25.8% | 27.1% | 26.4% | 30.8% | 24.6% | 26.9% | 27.3% | |
| 72.1% | 70.0% | 73.2% | 73.1% | 70.1% | 68.5% | 74.2% | 72.9% | 73.6% | 69.2% | 75.4% | 73.1% | 72.7% | |
| 19.3% | 25.4% | 19.5% | 18.7% | 18.2% | 25.0% | 19.5% | 25.3% | 19.8% | 27.3% | 22.2% | 41.2% | 27.7% | |
| 28.2% | 33.3% | 28.3% | 31.3% | 47.4% | 32.8% | 27.5% | 26.8% | 26.2% | 30.6% | 27.8% | 26.2% | 27.7% | |
| 48.2% | 62.9% | 53.0% | 52.2% | 67.7% | 59.9% | 44.7% | 47.6% | 43.2% | 51.7% | 45.4% | 67.3% | 52.0% | |
| 23.9% | 7.1% | 20.2% | 20.9% | 2.4% | 8.6% | 29.5% | 25.3% | 30.3% | 17.5% | 30.1% | 5.7% | 20.7% | |
| 2.2% | 3.4% | 2.3% | 2.2% | 1.9% | 1.8% | 2.2% | 2.3% | 2.0% | 2.0% | 2.2% | 2.2% | 2.1% | |
| 22.0% | 4.7% | 18.4% | 19.0% | 0.8% | 6.9% | 28.0% | 23.6% | 28.7% | 11.0% | 28.1% | 4.2% | 17.8% | |
| 3.2% | -0.2% | 3.7% | 2.4% | 0.0% | 0.8% | 4.5% | 3.0% | 3.7% | 2.6% | 4.0% | -2.4% | 1.9% | |
| 18.0% | 4.3% | 14.2% | 14.9% | -0.7% | 5.1% | 21.6% | 18.1% | 23.6% | 7.4% | 22.8% | 5.2% | 14.5% | |
| 31.3% | 14.4% | 28.1% | 29.3% | 14.6% | 13.8% | 41.2% | 40.4% | 39.3% | 22.1% | 36.4% | 33.6% | 32.7% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.